Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8857042 | 0.87 | FOLH1 (0.70) | PLA2G2AKDM4EALDH1A1FOLH1TP53 | |
| SCHEMBL9263671 | 0.85 | MCL1 (0.61) | KDM4E | |
| SCHEMBL8857055 | 0.84 | FOLH1 (0.62) | CNR2KDM4EALDH1A1FOLH1TP53 | |
| SCHEMBL8857072 | 0.81 | TP53 (0.64) | CNR2FOLH1TP53 | |
| SCHEMBL3807141 | 0.80 | KDM4E (0.57) | CNR2KDM4ELMNAHPGDALDH1A1 | |
| SCHEMBL8856992 | 0.79 | FOLH1 (0.55) | CNR2FOLH1TP53 | |
| SCHEMBL10758013 | 0.79 | CCR2 (0.55) | PLA2G2AKDM4E | |
| SCHEMBL10762568 | 0.79 | CCR2 (0.55) | PLA2G2AKDM4E | |
| SCHEMBL9264175 | 0.78 | PLA2G2A (0.78) | PLA2G2A | |
| SCHEMBL3567838 | 0.78 | FABP4 (0.56) | PLA2G2AFOLH1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082872-A1 | Indole-containing compounds with anti-tubulin and vascular targeting activity | BAYLOR UNIVERSITY | 2007-04-12 | — | — | US | disclosed |
| WO-2004099139-A1 | INDOLE-CONTAINING COMPOUNDS WITH ANTI-TUBULIN AND VASCULAR TARGETING ACTIVITY | BAYLOR UNIVERSITY (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082872-A1 | Indole-containing compounds with anti-tubulin and vascular targeting activity | TUBB3, TUBB1, TUBB | CNR2 2552/4885PLA2G2A 3975/4885KDM4E 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.